HAIFA, Israel, April 21, 2022 – MeMed (or “the Company”), a leader in the emerging field of advanced host-response technologies, today announces that it will host a webinar entitled “Differentiating Viral from Bacterial Infections with MeMed BV: Clinical Best Practices, Case Studies and Insights” aimed at solving challenging clinical cases and associated antibiotic treatment decisions in the emergency department.
The webinar will take place on April 28, 2022 at 1:00 pm EDT/ 7:00 pm CET/ 8:00 pm IL and will feature a discussion on real-world use of MeMed BV® and the associated patient care and antibiotic treatment benefit for emergency medicine practice decisions. MeMed BV® is a first-of-its kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes.
The webinar will feature Dr. Adi Klein, the Chief of Pediatrics at Hillel Yaffe Medical Center in Hadera, Israel and one one of Israel’s leading paediatric emergency physicians. Dr Klein was a principal investigator for the MeMed BV clinical studies and has been utilizing MeMed BV in clinical practice since 2014.
In the webinar, Dr. Klein will discuss her first-hand experience in clinical implementation, patient selection and interpreting MeMed BV results. She will present several real world patient case studies and close the session will with a short Q&A.
The session is aimed at supporting best practice integration into emergency or urgent care clinical workflow.
To register please click here.
About MeMed
Our mission is to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society. To learn more about MeMed and our solutions, please visit http://www.me-med.com
MeMed Contacts:
Will Harris, VP Marketing, MeMed
pr@me-med.com
Kfir Emmer, CFO, MeMed
kfir.emmer@me-med.com
Media relations contact:
Consilium Strategic Communications MeMed@consilium-comms.com
Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…
AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…
Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…
Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…